OSE Immunotherapeutics Highlights Preclinical Data of mRNA Therapeutic Platform to Treat Inflammatory and Autoimmune Disorders at FOCIS 2024
Shots:
- The IL-35 mRNA therapy expressed IL-35 immunosuppressive cytokine in the liver when transferred through lipid nanoparticles vector & showed acute & chronic autoimmune hepatitis inflammation suppression by inhibiting T & B cell activation in mouse models
- Moreover, certain autoantibody inhibition was also observed in the chronic hepatitis inflammatory model with mRNA IL-35 therapy
- OSE Immunotherapeutics’ mRNA platform uses lipid nanoparticles to transfer mRNA into inflammatory tissue, locally suppressing the immune response to treat inflammatory and autoimmune diseases
Ref: OSE Immunotherapeutics | Image: OSE Immunotherapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
